Document Detail


Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
MedLine Citation:
PMID:  6385264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine. Eligible patients included those with adequate renal and hepatic function, normal left ventricular ejection fraction, and those who had received previous treatment. When mitoxantrone was given alone in a once daily times five schedule, 5 of 12 acute lymphoblastic leukemia patients achieved complete remission; 4 of these patients had been refractory to reinduction and 1 to induction chemotherapy with anthracycline-containing treatments. Four of these patients had progressive disease, and three died during induction. Of 12 patients with acute myeloid leukemia, 1 had a complete remission, 1 had a partial remission, 8 had progressive disease, and 2 died during induction. Mitoxantrone was also found to be active in two patients in the blastic transformation of chronic myeloid leukemia with a response in one patient lasting 17 weeks. Combinations of mitoxantrone with vincristine sulfate and prednisone resulted in complete remission in four of nine acute lymphoblastic leukemia patients and one of four patients with Tdt-positive chronic myeloid leukemia in blast crisis. Three of these patients had not experienced a prior remission following anthracycline-containing treatments. Partial remission occurred in two of the acute lymphoblastic leukemia patients and one of the Tdt-positive chronic myeloid leukemia patients. Two of this latter group of patients died in induction. Treatment with mitoxantrone and cytarabine resulted in two acute myeloid leukemia patients achieving complete remission and one a partial remission; two patients had progressive disease, and one died in induction. No response was seen in a patient with Tdt-negative chronic myeloid leukemia after two courses of treatment. One patient with acute leukemia in the course of myelofibrosis died in induction. All the patients achieving complete remission are alive and have been in complete remission from 2 to 12 months. Side effects included mild nausea and vomiting in 9 of 13 patients treated with the mitoxantrone-vincristine sulfate-prednisone combination, and in 3 of 8 patients treated with the mitoxantrone-cytarabine combination. Other side effects of the combination treatments include drug-induced oral mucositis (of a lesser degree than with mitoxantrone alone), transient hepatic abnormalities, and infectious complications, such as sepsis, Candida sp colonization of the upper digestive tract, and soft tissue cellulitis, in a few patients.(ABSTRACT TRUNCATED AT 400 WORDS)
Authors:
P A Paciucci; J Cuttner; J F Holland
Related Documents :
21347214 - Two young patients with stroke in conjunction with migraineus headache.
8298474 - Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated ma...
6677564 - Cytogenetic studies in patients with hairy cell leukemia.
1937404 - Severe legionella pneumophila infection in a patient with hairy cell leukemia in partia...
9489084 - New patients presenting to their gp with dyspepsia: does helicobacter pylori eradicatio...
9329584 - Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphat...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Seminars in oncology     Volume:  11     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  1984 Sep 
Date Detail:
Created Date:  1984-11-01     Completed Date:  1984-11-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  36-40     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Aged
Anthraquinones / administration & dosage,  therapeutic use*,  toxicity
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*,  toxicity
Child
Child, Preschool
Clinical Trials as Topic
Cytarabine / administration & dosage
Female
Humans
Leukemia / drug therapy*
Leukemia, Lymphoid / drug therapy
Leukemia, Myeloid / drug therapy
Leukemia, Myeloid, Acute / drug therapy
Male
Middle Aged
Mitoxantrone
Prednisone / administration & dosage
Vincristine / administration & dosage
Grant Support
ID/Acronym/Agency:
CA-15936/CA/NCI NIH HHS; N01-CM 97275/CM/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Anthraquinones; 0/Antineoplastic Agents; 147-94-4/Cytarabine; 53-03-2/Prednisone; 57-22-7/Vincristine; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mitoxantrone in relapsed and refractory acute leukemia.
Next Document:  Mitoxantrone in the treatment of relapsed and refractory acute leukemia.